|
DAWN | Day One Biopharmaceuticals, Inc. |
|
|
DAWN | Day One Biopharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.62 |
| Leverage | 12.24% |
| Market Cap | $ 724.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -109.8m |
| Margin | -80.04% |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and markets targeted therapies for patients with genetically defined cancers. The company is headquartered in South San Francisco, California.